Odevixibat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Odevixibat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Odevixibat can convert its Small molecule drug profile and ISBT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Odevixibat (query alias: Odevixibat) |
|---|---|
| Modality / target | Small molecule drug; ISBT; ISBT inhibitors |
| Highest global status | Approved |
| Originator | Albireo Pharma, Inc. |
| Active developers | Medison Pharma Ltd., Ipsen (Tianjin) Pharmaceutical Trade Co. Ltd., Albireo AB |
The MCP disease footprint includes Cholestatic pruritus, Pruritus, Alagille Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20255202 | Phase 4 | 进行中 （招募中） | 2 | Not disclosed |
| JPRN-jRCT2041240037 | Phase 3 | 募集終了 | 10 | - Change from baseline in scratching to Month 6 (Weeks 21 to 24) as measured by the ObsRO - Change in serum bile acid levels from baseline to the average of Week 20 and Week 24 - Evaluation of adverse events (AEs) including severity and relatedness to study drug |
| JPRN-jRCT2061230022 | Phase 3 | Not Recruiting | 6 | 〇用量調整期 ・ベースラインから24 週時までに空腹時血清中胆汁酸濃度が70%以上低下した被験者、又は24 週間の投与後に空腹時血清中胆汁酸濃度が70 μmol/L 以下に到達した被験者の割合 注）空腹時血清中胆汁酸濃度は、当該評価時点の2 回のVisit での測定値の平均として計算する。 ・観察者報告アウトカム（ObsRO）による24 週間（用量調整期）の痒み評価が改善した割合 注）痒み評価が改善とは、ObsRO の引っ掻きスコアが1 以下、又はObsRO に基づくベースラインから1 ポイント以上の低下と定義される。 〇継続投与期 ・ベースラインから72 週間（継続投与期）の血清中胆汁酸濃度の変化 ・ObsRO による72 週間（継続投与期）の痒み評価が改善した割合 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
Phase 3; n=116; evaluation: not stated. Reported fields: Change From Baseline in Serum Bile Acids(Mean) = -57.97 micromole per liter (µmol/L) (Standard Deviation, 137.990); Change From Baseline in Serum Bile Acids(Mean) = -139.84 micromole per liter (µmol/L) (Standard Deviation, 172.070); -
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Phase 3; n=116; evaluation: Positive. Reported fields: -; Pruritus(72-week) = -1 Point
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Phase 3; n=50; evaluation: Positive. Reported fields: Pruritus = At week 72, 93 percent (n=28/30) of patients who received Bylvay throughout the 24 weeks ASSERT trial and 77 percent (n=10/13) of those who transitioned from placebo to Bylvay at week 24 experienced a clinically meaningful ≥1 point reduction in pruritus score. ; Pruritus = At week 72, 93 percent (n=28/30) of patients who received Bylvay throughout the 24 weeks ASSERT trial and 77 percent (n=10/13) of those who transitioned from placebo to Bylvay at week 24 experienced a clinically meaningful ≥1 point reduction in pruritus score.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Odevixibat addresses Cholestatic pruritus, Pruritus, Alagille Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-01-09 | Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio | Approved | Financial terms not disclosed |
| 2022-09-22 | Albireo Pharma plans to monetize its royalty rights to Sagard for the global development of Bylvay, a treatment for PFIC. | Approved | US$115.0M stated total |
| 2022-08-16 | Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
